Omalizumab in children (Q34604574)

3 August 2017

1 reference

13 December 2019

Omalizumab in children (English)

1 reference

anti-idiotypic antibodies

3 August 2017

1 reference

13 December 2019

1 reference

13 December 2019

1 reference

27 September 2019

1 reference

13 December 2019

1 reference

Riccardo Castagnoli

4

0 references

Amelia Licari

object named as

Amelia Licari

1

0 references

Gian Luigi Marseglia

object named as

Gian Luigi Marseglia

7

0 references

author name string

Alessia Marseglia

2

1 reference

3 August 2017

Silvia Caimmi

3

1 reference

3 August 2017

Thomas Foiadelli

5

1 reference

3 August 2017

Salvatore Barberi

6

1 reference

3 August 2017

publication date

1 December 2014

6 references

3 August 2017

12 March 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

6 references

3 August 2017

12 March 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

16

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

491-502

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

3 August 2017

copyright license

start time

18 November 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Omalizumab: a review of its use in patients with chronic spontaneous urticaria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Current status of therapy with omalizumab in children

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab, an anti-immunoglobulin E antibody: state of the art.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab for asthma in adults and children

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab for treatment of allergic rhinitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Anti-IgE--emerging opportunities for Omalizumab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Diagnosis and treatment of urticaria and angioedema: a worldwide perspective

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Use of omalizumab in the treatment of food allergy and anaphylaxis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

International consensus on (ICON) pediatric asthma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Chronic spontaneous urticaria in children: itching for insight

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Effects of omalizumab on markers of inflammation in patients with allergic asthma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Safety and tolerability of omalizumab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

IgE in allergy and asthma today

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Effect of anti-IgE therapy in patients with peanut allergy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

7 July 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Omalizumab improves asthma-related quality of life in children with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Chronic idiopathic urticaria: prevalence and clinical course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4250568

Efficacy Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria With Different Background Therapy: Post Hoc Analysis Of Asteria I, Asteria II, and Glacial Studies

26 October 2018

1 reference

https://api.crossref.org/works/10.1007/S40272-014-0107-Z

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

21 January 2018

1 reference

12 December 2020

The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children

1 reference

12 December 2020

Treatment of recalcitrant atopic dermatitis with omalizumab

1 reference

12 December 2020

Efficacy of anti-IgE therapy in patients with atopic dermatitis

1 reference

12 December 2020

Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously

1 reference

12 December 2020

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

1 reference

12 December 2020

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

1 reference

12 December 2020

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

1 reference

12 December 2020

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey

1 reference

12 December 2020

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study

1 reference

12 December 2020

10.1007/S40272-014-0107-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference